Keytruda beaten by Summit’s bispecific in NSCLC - Yahoo Finance
WEB1 day ago · SMMT. On 8 September 2024, Summit Therapeutics and Akeso published results for the Phase III HARMONi-2 trial, which tested ivonescimab, a bispecific monoclonal antibody that binds to vascular ...
Why Summit Therapeutics Rocketed Over 60% Today - Yahoo …
WEBSep 9, 2024 · Shares of Summit Therapeutics (NASDAQ: SMMT) rocketed as high as 75.2% Monday, before settling into a 57.5% gain as of 1:27 PM EDT. The biotech firm released the results of a Phase III study on ...
Why Summit Therapeutics Stock Is Soaring Again Today - Yahoo …
WEBSep 12, 2024 · Shares of Summit Therapeutics (NASDAQ: SMMT) were soaring 22.5% higher as of 11:18 a.m. ET on Thursday. The gain came after the clinical-stage biopharmaceutical company revealed that it entered ...
Despite Win Over Keytruda, Summit’s NSCLC Bispecific Still Has ...
WEB3 days ago · Median progression free survival after nine months of follow-up was 11.14 months in the treatment arm vs. 5.82 months in the Keytruda group. Summit’s bispecific cut the risk of disease progression or death by nearly 50% compared to Keytruda. HARMONi-2 included a variety of patient subgroups, including …
Press Releases - Summit Therapeutics
WEBFeb 20, 2024 · Summit Therapeutics Announces Timing of Rights Offering for Up to $500 Million. January 20, 2023. Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody. January 5, 2023. Summit Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference.
WCLC: Summit trumpets data with Keytruda challenger
WEBSep 9, 2024 · Summit Therapeutics and Akeso's ivonescimab tops Merck's Keytruda in head-to-head phase 3 trial in first-line NSCLC, reported at WCLC. ... Get in-depth news, opinions and features on pharma and ...
Summit Therapeutics’ stock surges as lung-cancer treatment vies …
WEBMay 30, 2024 · Shares of Summit Therapeutics Inc. SMMT jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.’s blockbuster Keytruda in a late-stage...
Summit Therapeutics' stock surges as lung-cancer treatment vies …
WEBMay 30, 2024 · Shares of Summit Therapeutics Inc. (SMMT) jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc.'s blockbuster Keytruda in a late-stage...
Summit Therapeutics Secures $235 Million in Funding from …
WEBSep 12, 2024 · Summit Therapeutics Inc. (SMMT) is making waves today with a major announcement that has sent its stock price soaring 20.77% to $27.42 as of 12:48 PM EDT. The company has successfully raised a substantial $235 million in a private placement, attracting significant interest from both institutional …
Summit Therapeutics Announces Initial Indications for Clinical …
WEBMay 3, 2023 · Summit intends to begin multiple Phase III clinical trials in its license territories in 2023. Over 750 patients have been dosed with ivonescimab in clinical studies in China and Australia....
Skip to content